Gilead: HIV Franchise Woes Highlight Cancer Follies
Gilead’s HIV franchise generated $19.612B in 2024, but faces future funding challenges. Learn why GILD stock is a "Hold" amid ...
‘Handmaid’s Tale’ exec reveals when spinoff ‘The Testaments’ will begin filming — and it’s sooner than you think
The Post caught up with several stars and crew members of “The Handmaid’s Tale” at the show’s sixth and final season premiere ...
Making Progress for People Affected by Liver Disease
The liver is one of the body’s most vital organs, working tirelessly behind the scenes to detoxify, regulate metabolism, ...
Gilead’s HIV Treatments Could Face Headwinds. Why the Stock Will Still Rise.
Gilead Sciences stock has room to climb, and investors shouldn’t overlook the company’s impressive record in navigating HIV policy, Citi Research says. Analysts led by Geoff Meacham reiterated a Buy ...
Zacks Investment Research on MSN3d
Gilead Sciences (GILD) Ascends While Market Falls: Some Facts to Note
In the latest market close, Gilead Sciences (GILD) reached $112.39, with a +0.45% movement compared to the previous day. The stock outperformed the S&P 500, which registered a daily loss of 4.84%. On ...
'The Handmaid's Tale' to continue in new series with Ann Dowd and more
Hulu announced that it is developing a series based on Margaret Atwood's 2019 novel "The Testaments," which is a follow-up to ...
Gilead Sciences CEO's pay climbed to $23.7 million
Gilead Sciences Inc. CEO Daniel O'Day's compensation rose 4.8% last year to $23.7 million — roughly $97 for every buck made ...
Observer3d
‘The Handmaid’s Tale’ Season 6 Review: Warnings And Entertainment Continue to the End
This final season may be more of a cliffhanger than a conclusion. (A sequel is in the works.) The question it asks is: how ...
CSRWire4d
Discovering a Breakthrough: Gilead’s Long-Standing Commitment to Helping Change the Course of HIV
Tomas Cihlar knew all too well that despite initial successes with combination treatment, HIV was firmly holding ground ...